Cybin Inc

💬 “With regular psilocybin, you might be waiting an hour for effects to kick in, with our deuterated psilocin, we see effects in about 15 minutes.” Doug Drysdale, CEO of Cybin Inc, breaks down how modifying classic psychedelics like psilocybin and DMT could lead to faster-acting, more scalable treatments. 🎧 Over the next 2 weeks, we’re sharing a clip a day from guests on Season 2 of Power to the Patients ahead of the Season 3 launch. Link to episode here: https://lnkd.in/gUzcg55E

Exciting News from Cybin Inc! We are proud to announce that CenExel iResearch Atlanta is participating in Cybin's Strategic Partnership Agreement (SPA) program, supporting the Phase 3 development of CYB003, a novel treatment for Major Depressive Disorder. 📖 "This level of cooperation will streamline trial operations and has the potential to reduce time to completion." 👏 A special thank you to Dr. Kimball Johnson, Medical Director of CenExel iResearch Atlanta, for her continued leadership in advancing mental health research. ➡️ Read here: https://lnkd.in/gHqG_4NQ

“This strategic partnership agreement model serves to take advantage of the deep expertise of each individual site and ensure that protocols and best practices are shared consistently,” said #Cybin CEO Doug Drysdale “This level of cooperation will streamline trial operations and has the potential to reduce time to completion.” Learn more: https://loom.ly/4r6Nng0 Segal Trials

“Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals,” said #Cybin CEO Doug Drysdale.     "Osmind’s extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments such as #CYB003 and #CYB004."    Learn more: https://lnkd.in/ggsH2VvR

"What we’re seeing with our treatment is, after just two doses, and I don’t mean two doses a week or two doses a month, I mean just two doses, we see 75% of patients in remission from their depression and 71% still in remission one year later." Read #Cybin CEO Doug Drysdale's full interview: https://loom.ly/8zgFW0s Invezz

This #WorldHealthDay, we at #Cybin are committed to changing minds and revolutionizing mental healthcare for the benefit of patients everywhere.   With breakthrough therapies in development to meet global unmet needs in depression and anxiety, we're paving the way for a world where mental health treatment is more effective and accessible for all.

As the holy month of Ramadan concludes, Cybin extends heartfelt wishes to all celebrating Eid al-Fitr. May this joyous occasion bring peace, happiness, and unity to you and your loved ones. #EidFitr #EidMubarak

Rapid and durable effects have been observed in #DMT studies, with: ✓ Improvements in anxiety and well-being scores ✓ Safe and well-tolerated intramuscular route ✓ Safe and well-tolerated when co-administered with SSRIs Learn more: https://loom.ly/WEGP3es

#GAD is characterized by persistent and excessive worry about health, work, social interactions, and everyday routines. Symptoms include restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. Learn more about #CYB004 — #Cybin’s proprietary, deuterated DMT molecule in a Phase 2 study for GAD: https://loom.ly/WEGP3es

This St. Patrick's Day, let's not just count our luck but also the strides we're making towards mental wellness. At Cybin, we're pioneering the path to revolutionize mental health care with innovative, safe, and effective therapeutics. Here's to a future where every mind finds its rainbow.   #StPatricksDay #MentalHealthInnovation #Cybin